AR PROTAC Composition for Degrading Resistant Androgen Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate and ovarian cancers, particularly castration-resistant prostate cancer, are limited by the development of resistance mechanisms in androgen receptor (AR) due to mutations and overexpression, necessitating new therapeutic approaches to target AR effectively.
Innovation Solution
Development of Androgen Receptor PROTACs containing 2,4-dioxotetrahydropyrimidinyl derivatives that bind cereblon, forming a ternary complex to ubiquitinate and degrade mutated and overexpressed AR, utilizing a compound structure that includes an androgen receptor binding moiety, a linker, and a cereblon binding moiety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional androgen ablation therapy is used to treat prostate cancer, then cancer treatment effectiveness is improved, but resistance develops leading to disease progression
Solution Approach 1:
The invention extracts and degrades the androgen receptor protein itself using PROTACs, separating the target protein from the treatment mechanism. By directly targeting AR for proteasomal degradation rather than blocking its function, the therapy eliminates the receptor's presence in cancer cells, overcoming resistance mechanisms that arise from receptor overexpression or mutation.
Solution Approach 2:
The invention changes the pharmacological approach from androgen deprivation to direct protein degradation. By modifying the mechanism of action to target AR for degradation rather than simply blocking androgen binding, the therapy addresses resistant clones that maintain receptor expression but become resistant to conventional androgen ablation.
2Reliability
If AR binding affinity is increased to improve treatment response, then cancer cell growth is inhibited, but resistance mechanisms including AR overexpression and mutations occur
Solution Approach 1:
The PROTAC approach extracts and removes the AR protein from cancer cells through targeted degradation. This directly addresses AR overexpression and mutation-induced resistance by eliminating the receptor rather than attempting to block its function, thereby maintaining treatment effectiveness despite varying AR states.
Solution Approach 2:
Instead of attempting to bind to and block AR (conventional approach), the invention inverts the strategy by using PROTACs to recruit E3 ligases for AR degradation. This reverse approach - rather than inhibiting receptor function - leads to complete receptor elimination, overcoming resistance to conventional androgen ablation therapy.
3Reliability
If PROTACs are designed to target mutated and overexpressed AR forms, then treatment efficacy against resistant cancer cells is improved, but compound structure and mechanism complexity increases
Solution Approach 1:
The PROTAC compound is segmented into distinct functional modules: an AR binding moiety, a linker, and a cereblon binding moiety. This segmentation allows each component to be optimized independently for its specific function, facilitating the design of effective PROTACs that target mutated and overexpressed AR forms despite the increased overall structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTACs demonstrate the ability to degrade mutated and overexpressed AR forms in prostate cancer cell lines, offering a potential therapeutic benefit for prostate and ovarian cancers by targeting AR for destruction.
Implementation Method 1
The PROTAC generates a ternary complex of all of the components needed to ubiquitinate the target, leading to ubiquitination and subsequently degradation of the target
Implementation Method 2
The Ubiquitin Proteosome Pathway System (UPS) is a pathway for degrading regulatory proteins as well as misfolded or abnormal proteins
Data Source
AI summary
Certain Androgen receptor PROTAC (PROteolysis TArgeting Chimera) compounds contain a series of 2,4-dioxotetrahydropyrimidinyl derivatives that bind cereblon. The PROTAC compounds may be viewed as being comprised of an androgen receptor binding moieties, a linker and a cereblon binding moiety or degron. Medical uses of these PROTAC compounds are also disclosed.